Progress against follicular lymphoma

Jonathan H Schatz, Elisa Oricchio, Soham D Puvvada, H. Guido Wendel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose of Review: To share the recent progress in research and new therapies against follicular lymphoma and highlight the exciting opportunities to improve the treatment of follicular lymphoma. RECENT FINDINGS: Follicular lymphoma has been somewhat neglected by the research community, but recent genomic studies have identified key genetic lesions in follicular lymphoma. In addition, a new murine model is available to explore the function of these lesions in the development, progression, and treatment of follicular lymphoma. Moreover, new small-molecule inhibitors are now available that target key pathways in follicular lymphoma including B-cell receptor signaling and histone modifiers. SUMMARY: Follicular lymphoma is a very common and still incurable form of lymphoma. However, recent genomic and in-vivo biological studies are beginning to unveil the molecular drivers of follicular lymphoma. This coincides with the development of effective small-molecule inhibitors against key targets. Together these developments suggest that we are at a long overdue watershed moment in the treatment of follicular lymphoma.

Original languageEnglish (US)
Pages (from-to)320-326
Number of pages7
JournalCurrent Opinion in Hematology
Volume20
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Follicular Lymphoma
Metagenomics
Research
Histones
Lymphoma
B-Lymphocytes

Keywords

  • Experimental models
  • Follicular lymphoma
  • Genomics
  • Pathogenesis
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Progress against follicular lymphoma. / Schatz, Jonathan H; Oricchio, Elisa; Puvvada, Soham D; Wendel, H. Guido.

In: Current Opinion in Hematology, Vol. 20, No. 4, 07.2013, p. 320-326.

Research output: Contribution to journalArticle

Schatz, Jonathan H ; Oricchio, Elisa ; Puvvada, Soham D ; Wendel, H. Guido. / Progress against follicular lymphoma. In: Current Opinion in Hematology. 2013 ; Vol. 20, No. 4. pp. 320-326.
@article{28511dfd740b4d5c9a4e15c894d7499d,
title = "Progress against follicular lymphoma",
abstract = "Purpose of Review: To share the recent progress in research and new therapies against follicular lymphoma and highlight the exciting opportunities to improve the treatment of follicular lymphoma. RECENT FINDINGS: Follicular lymphoma has been somewhat neglected by the research community, but recent genomic studies have identified key genetic lesions in follicular lymphoma. In addition, a new murine model is available to explore the function of these lesions in the development, progression, and treatment of follicular lymphoma. Moreover, new small-molecule inhibitors are now available that target key pathways in follicular lymphoma including B-cell receptor signaling and histone modifiers. SUMMARY: Follicular lymphoma is a very common and still incurable form of lymphoma. However, recent genomic and in-vivo biological studies are beginning to unveil the molecular drivers of follicular lymphoma. This coincides with the development of effective small-molecule inhibitors against key targets. Together these developments suggest that we are at a long overdue watershed moment in the treatment of follicular lymphoma.",
keywords = "Experimental models, Follicular lymphoma, Genomics, Pathogenesis, Therapy",
author = "Schatz, {Jonathan H} and Elisa Oricchio and Puvvada, {Soham D} and Wendel, {H. Guido}",
year = "2013",
month = "7",
doi = "10.1097/MOH.0b013e3283622ed6",
language = "English (US)",
volume = "20",
pages = "320--326",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Progress against follicular lymphoma

AU - Schatz, Jonathan H

AU - Oricchio, Elisa

AU - Puvvada, Soham D

AU - Wendel, H. Guido

PY - 2013/7

Y1 - 2013/7

N2 - Purpose of Review: To share the recent progress in research and new therapies against follicular lymphoma and highlight the exciting opportunities to improve the treatment of follicular lymphoma. RECENT FINDINGS: Follicular lymphoma has been somewhat neglected by the research community, but recent genomic studies have identified key genetic lesions in follicular lymphoma. In addition, a new murine model is available to explore the function of these lesions in the development, progression, and treatment of follicular lymphoma. Moreover, new small-molecule inhibitors are now available that target key pathways in follicular lymphoma including B-cell receptor signaling and histone modifiers. SUMMARY: Follicular lymphoma is a very common and still incurable form of lymphoma. However, recent genomic and in-vivo biological studies are beginning to unveil the molecular drivers of follicular lymphoma. This coincides with the development of effective small-molecule inhibitors against key targets. Together these developments suggest that we are at a long overdue watershed moment in the treatment of follicular lymphoma.

AB - Purpose of Review: To share the recent progress in research and new therapies against follicular lymphoma and highlight the exciting opportunities to improve the treatment of follicular lymphoma. RECENT FINDINGS: Follicular lymphoma has been somewhat neglected by the research community, but recent genomic studies have identified key genetic lesions in follicular lymphoma. In addition, a new murine model is available to explore the function of these lesions in the development, progression, and treatment of follicular lymphoma. Moreover, new small-molecule inhibitors are now available that target key pathways in follicular lymphoma including B-cell receptor signaling and histone modifiers. SUMMARY: Follicular lymphoma is a very common and still incurable form of lymphoma. However, recent genomic and in-vivo biological studies are beginning to unveil the molecular drivers of follicular lymphoma. This coincides with the development of effective small-molecule inhibitors against key targets. Together these developments suggest that we are at a long overdue watershed moment in the treatment of follicular lymphoma.

KW - Experimental models

KW - Follicular lymphoma

KW - Genomics

KW - Pathogenesis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84880222301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880222301&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e3283622ed6

DO - 10.1097/MOH.0b013e3283622ed6

M3 - Article

C2 - 23673338

AN - SCOPUS:84880222301

VL - 20

SP - 320

EP - 326

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -